plicamycin has been researched along with Adenocarcinoma, Basal Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WC; Chen, SY; Hsu, TI; Huang, ST; Hung, JJ; Su, WC; Wang, MC; Yeh, YM | 1 |
| Hisatsune, A; Isohama, Y; Kim, KC; Kuwahara, I; Lillehoj, EP; Lu, W; Miyata, T | 1 |
| Jia, Z; Le, X; Li, Q; Wang, L; Wei, D; Xie, K; Yao, J; Yuan, P; Zhang, J | 1 |
| Jia, Z; Le, X; Li, Q; Wang, H; Wang, L; Wei, D; Xie, K; Yao, J; Yuan, P; Zhang, J | 1 |
4 other study(ies) available for plicamycin and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Betulinic Acid; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin A2; Cysteine Endopeptidases; Down-Regulation; Endopeptidases; Female; HeLa Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Nuclear Proteins; Pentacyclic Triterpenes; Phosphorylation; Plicamycin; Proteasome Endopeptidase Complex; Retinoblastoma Protein; Sp1 Transcription Factor; Sumoylation; Transcription Factors; Transcriptome; Triterpenes; Ubiquitin; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2012 |
Neutrophil elastase stimulates MUC1 gene expression through increased Sp1 binding to the MUC1 promoter.
Topics: Adenocarcinoma; Binding Sites; Dactinomycin; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Leukocyte Elastase; Luciferases; Lung Neoplasms; Mucin-1; Plicamycin; Promoter Regions, Genetic; Protein Synthesis Inhibitors; Response Elements; RNA Stability; Sp1 Transcription Factor; Transcription Initiation Site; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2005 |
Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Drug Synergism; Female; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Plicamycin; Promoter Regions, Genetic; Sp1 Transcription Factor; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Pancreatic Neoplasms; Plicamycin; RNA, Small Interfering; Sp1 Transcription Factor; Xenograft Model Antitumor Assays | 2007 |